GlassScriptPhysician profile
Jason Chang
NPI 1891988408
$2,399.47
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $311 · 2021: $551 · 2022: $607 · 2023: $524 · 2024: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.90 | 2021-2024 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $301.48 | 2019-2022 | |
| Neurelis, INC. | $166.54 | 2020-2023 | Valtoco |
| Merz North America, INC. | $125.05 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.40 | 2024 | Relistor |
| Sk Life Science, INC. | $116.44 | 2021-2023 | |
| Eisai INC. | $105.76 | 2021-2023 | |
| Lundbeck LLC | $88.21 | 2021-2023 | Vyepti |
| Livanova USA, INC. | $80.68 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $50.06 | 2023 | Dysport |
| Amneal Pharmaceuticals LLC | $45.59 | 2022-2023 | Rytary |
| Teva Pharmaceuticals USA, INC. | $45.44 | 2022 | |
| Genzyme Corporation | $45.00 | 2019 | |
| Medtronic USA, INC. | $44.89 | 2019 | |
| Merz Pharmaceuticals, LLC | $39.81 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.89 | 2021 | |
| Mallinckrodt Hospital Products INC. | $28.53 | 2021 | |
| Upsher-Smith Laboratories LLC | $28.23 | 2021 | |
| Grifols USA, LLC | $27.30 | 2020 | |
| Mallinckrodt Enterprises LLC | $24.36 | 2019 | |
| Csl Behring | $23.46 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.33 | 2021 | |
| Biogen, INC. | $22.58 | 2021 | |
| Cala Health, INC. | $21.61 | 2023 | Cala Trio |
| Nevro Corp. | $20.89 | 2023 | Senza |
| Neurocrine Biosciences, INC. | $19.75 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.79 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $17.63 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.68 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.98 | 2021 | |
| Spr Therapeutics, INC | $11.21 | 2024 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.